Publicação

Synergy valuation in the Pfizer - seagen acquisition - influencing factors on abnormal returns in R & D intensive industries for Us acquirers

Ver documento

Detalhes bibliográficos
Resumo:This thesis examines the Pfizer-Seagen acquisition, a pivotal deal in the pharmaceutical industry. It starts with a literature review on valuation methods and further analysesthe strategic motivations and financial implications of mergers and acquisitions in the industry. The thesis assesses both companies' market positions, strategies, and financial health, to perform two comprehensive standalone valuations. It also conducts a combined valuation to explore potential synergies and economically feasible offer prices, comparing these to Pfizer's announced offer. The supplementary individual part analyses the factors influencing abnormal stock price returns in R&D intensive industries for U.S. acquirers around M&A announcement.
Autores principais:Schultz, Noah Michael
Assunto:Mergers and acquisitions Valuation Pharmaceutical industry Pfizer Seagen
Ano:2024
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso aberto
Instituição associada:Universidade Nova de Lisboa
Idioma:inglês
Origem:Repositório Institucional da UNL
Descrição
Resumo:This thesis examines the Pfizer-Seagen acquisition, a pivotal deal in the pharmaceutical industry. It starts with a literature review on valuation methods and further analysesthe strategic motivations and financial implications of mergers and acquisitions in the industry. The thesis assesses both companies' market positions, strategies, and financial health, to perform two comprehensive standalone valuations. It also conducts a combined valuation to explore potential synergies and economically feasible offer prices, comparing these to Pfizer's announced offer. The supplementary individual part analyses the factors influencing abnormal stock price returns in R&D intensive industries for U.S. acquirers around M&A announcement.